AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Other Events

AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events.

On January31, 2017, AveXis,Inc. (the Company) issued a
press release announcing that the European Medicines Agency has
granted access into its PRIority MEdicines (PRIME) program for
AVXS-101, the Companys proprietary gene therapy, for the
treatment of spinal muscular atrophy (SMA) Type 1. The
full text of the Companys press release regarding the
announcement is filed as Exhibit99.1 to this Current Report on
Form8-K and is incorporated herein by reference.

On February6, 2017, the Company issued a press release announcing
the trial design for its European pivotal study of AVXS-101 in
SMA Type 1 patients. The full text of the Companys press release
regarding the announcement is filed as Exhibit99.2 to this
Current Report on Form8-K and is incorporated herein by
reference.

Item 9.01 Financial Statements and
Exhibits.

(d)Exhibits

Exhibit

Number

ExhibitDescription

99.1

Press Release, dated January31, 2017, titled AveXis Gene
Therapy AVXS-101 Granted Access into EMA PRIME Program for
Spinal Muscular Atrophy Type 1.

99.2

Press Release, dated February6, 2017, titled AveXis
Announces Single-Arm Design for European Pivotal Study of
AVXS-101 in SMA Type 1 Patients.


About AVEXIS, INC. (NASDAQ:AVXS)

AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.

AVEXIS, INC. (NASDAQ:AVXS) Recent Trading Information

AVEXIS, INC. (NASDAQ:AVXS) closed its last trading session 00.00 at 58.98 with 488,253 shares trading hands.

An ad to help with our costs